Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein

Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling

(2011) Olaf Weber et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The safety of healthy volunteers in First-in-Man trials – an analysis of studies conducted at the Bayer in-house ward from 2000 to 2005

(2011) G. Wensing et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Novel tetrahydrochinoline derived CETP inhibitors

(2010) Carsten Schmeck et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform

(2009) Thomas A. Rano et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The end of the road for CETP inhibitors after torcetrapib?

(2009) Tisha Joy et al.   CURRENT OPINION IN CARDIOLOGY

Design, Synthesis, and Biological Evaluation of (2R,αS)-3,4-Dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-α-(trifluoromethyl)-1(2H)-quinolineethanol as Potent and Orally Active Cholesteryl Ester Transfer Protein Inhibitor

(2009) Gee-Hong Kuo et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cholesteryl Ester Transfer Protein (CETP) Inhibitors: Is There Life After Torcetrapib?

(2008) Hemanth Neeli et al.   CARDIOLOGY CLINICS

JTT-705: is there still future for a CETP inhibitor after torcetrapib?

(2008) Alexander JM Rennings et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS